Molecular Mechanisms and Potential Therapeutic Reversal of Pancreatic Cancer-Induced Immune Evasion

Pancreatic cancer ranks high among the causes of cancer-related mortality. The prognosis of this grim condition has not improved significantly over the past 50 years, despite advancement in imaging techniques, cancer genetics and treatment modalities. Due to the relative difficulty in the early detection of pancreatic tumors, as low as 20% of patients are eligible for potentially curative surgery; moreover, chemotherapy and radiotherapy (RT) do not confer a great benefit in the overall survival of the patients. Currently, emerging developments in immunotherapy have yet to bring a significant clinical advantage among pancreatic cancer patients. In fact, pancreatic tumor-driven immune evasion possesses one of the greatest challenges leading to immunotherapeutic resistance. Most of the immune escape pathways are innate, while poor priming of hosts’ immune response and immunoediting constitute the adaptive immunosuppressive machinery. In this review, we extensively discuss the pathway perturbations undermining the anti-tumor immunity specific to pancreatic cancer. We also explore feasible up-and-coming therapeutic strategies that may restore immunity and address therapeutic resistance, bringing hope to eliminate the status quo in pancreatic cancer prognosis.

[1]  G. Berchem,et al.  Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti–PD-1/PD-L1 immunotherapy , 2020, Science Advances.

[2]  J. Debnath,et al.  Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I , 2020, Nature.

[3]  E. Jaffee,et al.  Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future. , 2020, The Lancet. Oncology.

[4]  R. Vonderheide.  CD40 Agonist Antibodies in Cancer Immunotherapy. , 2020, Annual review of medicine.

[5]  C. Swanton,et al.  Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses , 2020, Cell reports.

[6]  F. Shimamoto,et al.  m6A demethylase ALKBH5 inhibits pancreatic cancer tumorigenesis by decreasing WIF-1 RNA methylation and mediating Wnt signaling , 2020, Molecular Cancer.

[7]  R. Herbst,et al.  Frontline immunotherapy for NSCLC — the tale of the tail , 2020, Nature Reviews Clinical Oncology.

[8]  Sunil Kumar Singh,et al.  Mitogen-Activated Protein Kinase Inhibitors and T-Cell-Dependent Immunotherapy in Cancer , 2020, Pharmaceuticals.

[9]  S. Spranger,et al.  Modulation of the immune microenvironment by tumor-intrinsic oncogenic signaling , 2019, The Journal of cell biology.

[10]  Jennifer L Moseley,et al.  Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study , 2019, Clinical Cancer Research.

[11]  Jung Kyoon Choi,et al.  DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load , 2019, Nature Communications.

[12]  C. Mai,et al.  The synergism of Clinacanthus nutans Lindau extracts with gemcitabine: downregulation of anti-apoptotic markers in squamous pancreatic ductal adenocarcinoma , 2019, BMC Complementary and Alternative Medicine.

[13]  Zhen Luo,et al.  Hypoxia-induced shedding of MICA and HIF1A-mediated immune escape of pancreatic cancer cells from NK cells: role of circ_0000977/miR-153 axis , 2019, RNA biology.

[14]  A. Azzariti,et al.  Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study , 2019, Cancers.

[15]  I. Treilleux,et al.  MEDIPLEX: A phase 1 study of durvalumab (D) combined with pexidartinib (P) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC). , 2019, Journal of Clinical Oncology.

[16]  E. Jaffee,et al.  Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study) , 2019, Clinical Cancer Research.

[17]  M. Fraga,et al.  Epigenetics in cancer therapy and nanomedicine , 2019, Clinical Epigenetics.

[18]  Shichun Tu,et al.  Exosomal miRNA-107 induces myeloid-derived suppressor cell expansion in gastric cancer , 2019, Cancer management and research.

[19]  M. Riese,et al.  STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models , 2019, Journal of Immunotherapy for Cancer.

[20]  C. Mai,et al.  Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment , 2019, Journal of experimental & clinical cancer research : CR.

[21]  V. Pillarisetty,et al.  Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma , 2019, Clinical and Translational Medicine.

[22]  G. Evan,et al.  Myc instructs and maintains pancreatic adenocarcinoma phenotype , 2019, bioRxiv.

[23]  M. Kershaw,et al.  Genetic Redirection of T Cells for the Treatment of Pancreatic Cancer , 2019, Front. Oncol..

[24]  E. Collisson,et al.  Molecular subtypes of pancreatic cancer , 2019, Nature Reviews Gastroenterology & Hepatology.

[25]  Y. Hashimoto,et al.  Results from phase I study of the oncolytic viral immunotherapy agent canerpaturev (C-REV) in combination with gemcitabine plus nab-paclitaxel for unresectable pancreatic cancer. , 2019, Journal of Clinical Oncology.

[26]  J. Luke,et al.  WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers , 2019, Clinical Cancer Research.

[27]  E. Jaffee,et al.  Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs , 2018, Cancer Immunology Research.

[28]  C. Paweletz,et al.  Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer. , 2018, Cancer discovery.

[29]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[30]  B. Shi,et al.  Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer. , 2018, Journal of the National Cancer Institute.

[31]  D. Torigian,et al.  Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial. , 2018, Gastroenterology.

[32]  R. Schulick,et al.  Immunotherapy for pancreatic cancer: Barriers and breakthroughs , 2018, Annals of gastroenterological surgery.

[33]  R. Andersson,et al.  Targeting dendritic cells in pancreatic ductal adenocarcinoma , 2018, Cancer Cell International.

[34]  D. Munn,et al.  Phase 2 trial of the IDO pathway inhibitor indoximod plus checkpoint inhibition for the treatment of patients with advanced melanoma. , 2018 .

[35]  M. Korc.  Beyond Kras: MYC Rules in Pancreatic Cancer , 2018, Cellular and molecular gastroenterology and hepatology.

[36]  B. Somer,et al.  Phase 2 trial of the IDO pathway inhibitor indoximod plus gemcitabine / nab-paclitaxel for the treatment of patients with metastatic pancreas cancer. , 2018 .

[37]  C. Mai,et al.  Identification of inhibitors synergizing gemcitabine sensitivity in the squamous subtype of pancreatic ductal adenocarcinoma (PDAC) , 2018, Apoptosis.

[38]  P. Marcato,et al.  Dying to Be Noticed: Epigenetic Regulation of Immunogenic Cell Death for Cancer Immunotherapy , 2018, Front. Immunol..

[39]  J. Soria,et al.  Epigenetic modifiers as new immunomodulatory therapies in solid tumours , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  T. Gajewski,et al.  Mechanisms of Tumor Cell–Intrinsic Immune Evasion , 2018 .

[41]  Kwok-Kin Wong,et al.  Autophagy Sustains Pancreatic Cancer Growth through Both Cell-Autonomous and Nonautonomous Mechanisms. , 2018, Cancer discovery.

[42]  Joon-Oh Park,et al.  Efficacy and tolerability of tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma. , 2018 .

[43]  G. Kroemer,et al.  Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies. , 2017, Trends in immunology.

[44]  C. Mai,et al.  Targeting Legumain As a Novel Therapeutic Strategy in Cancers. , 2017, Current drug targets.

[45]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[46]  Jingchun Zeng,et al.  Evaluation of K-ras and p53 expression in pancreatic adenocarcinoma using the cancer genome atlas , 2017, PloS one.

[47]  William A. Flavahan,et al.  Epigenetic plasticity and the hallmarks of cancer , 2017, Science.

[48]  M. Falasca,et al.  Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies , 2017, International journal of molecular sciences.

[49]  S. Demaria,et al.  PTEN at the interface of immune tolerance and tumor suppression , 2017, Frontiers in Biology.

[50]  K. Wittrup,et al.  Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors , 2017, The Journal of clinical investigation.

[51]  Yan Cui,et al.  Local Activation of p53 in the Tumor Microenvironment Overcomes Immune Suppression and Enhances Antitumor Immunity. , 2017, Cancer research.

[52]  Huidong Shi,et al.  The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion , 2017, Journal of the National Cancer Institute.

[53]  K. Tsuta,et al.  PD-L1 expression in pancreatic ductal adenocarcinoma is a poor prognostic factor in patients with high CD8+ tumor-infiltrating lymphocytes: highly sensitive detection using phosphor-integrated dot staining , 2017, International Journal of Clinical Oncology.

[54]  C. Mai,et al.  Cudraflavone C Induces Tumor-Specific Apoptosis in Colorectal Cancer Cells through Inhibition of the Phosphoinositide 3-Kinase (PI3K)-AKT Pathway , 2017, PloS one.

[55]  E. El Rassy,et al.  Dilemma of first line regimens in metastatic pancreatic adenocarcinoma , 2016, World journal of gastroenterology.

[56]  O. Sansom,et al.  PD‐L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy , 2016, EMBO molecular medicine.

[57]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[58]  B. Stanger,et al.  Lack of immunoediting in murine pancreatic cancer reversed with neoantigen. , 2016, JCI insight.

[59]  Elizabeth E. Hull,et al.  HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory Diseases , 2016, BioMed research international.

[60]  Shannon M. White,et al.  Yes-Associated Protein Mediates Immune Reprogramming in Pancreatic Ductal Adenocarcinoma , 2016, Oncogene.

[61]  Song-Cheol Kim,et al.  Pancreatic adenocarcinoma up-regulated factor (PAUF) enhances the accumulation and functional activity of myeloid-derived suppressor cells (MDSCs) in pancreatic cancer , 2016, Oncotarget.

[62]  Xiuyan Wang,et al.  Clinical manufacturing of CAR T cells: foundation of a promising therapy , 2016, Molecular therapy oncolytics.

[63]  D. Weaver,et al.  Targeting Focal Adhesion Kinase Renders Pancreatic Cancers Responsive to Checkpoint Immunotherapy , 2016, Nature Medicine.

[64]  R. Bourgon,et al.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.

[65]  D. Felsher,et al.  MYC regulates the antitumor immune response through CD47 and PD-L1 , 2016, Science.

[66]  Christine A Iacobuzio-Donahue,et al.  Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular-fibrosis and tumor progression , 2016, Nature Medicine.

[67]  C. Zahnow,et al.  Combining Epigenetic and Immunotherapy to Combat Cancer. , 2016, Cancer research.

[68]  M. Belvin,et al.  MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade. , 2016, Immunity.

[69]  Jing Wang,et al.  STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. , 2016, Cancer research.

[70]  J. McQuade,et al.  Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. , 2016, Cancer discovery.

[71]  P. Hwu,et al.  Targeting the indoleamine 2,3-dioxygenase pathway in cancer , 2015, Journal of Immunotherapy for Cancer.

[72]  H. Kaufman,et al.  Oncolytic viruses: a new class of immunotherapy drugs , 2015, Nature Reviews Drug Discovery.

[73]  D. Linehan,et al.  CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. , 2015, Cancer research.

[74]  R. Hua,et al.  Decreased LKB1 predicts poor prognosis in Pancreatic Ductal Adenocarcinoma , 2015, Scientific Reports.

[75]  M. Parra.  Class IIa HDACs – new insights into their functions in physiology and pathology , 2015, The FEBS journal.

[76]  Xiong Chen,et al.  Hypoxia-mediated immune evasion of pancreatic carcinoma cells. , 2015, Molecular medicine reports.

[77]  R. Andersson,et al.  Update on the management of pancreatic cancer: surgery is not enough. , 2015, World journal of gastroenterology.

[78]  E. Kleinerman,et al.  The Narrow-Spectrum HDAC Inhibitor Entinostat Enhances NKG2D Expression Without NK Cell Toxicity, Leading to Enhanced Recognition of Cancer Cells , 2015, Pharmaceutical Research.

[79]  M. Hidalgo,et al.  Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms , 2015, Clinical Cancer Research.

[80]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[81]  Weiqing Wang,et al.  Targeting β-catenin signaling for therapeutic intervention in MEN1-deficient pancreatic neuroendocrine tumours , 2014, Nature Communications.

[82]  M. Loda,et al.  Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer , 2014, Clinical Cancer Research.

[83]  Y. Kluger,et al.  PTEN functions as a melanoma tumor suppressor by promoting host immune response , 2014, Oncogene.

[84]  E. Dees,et al.  A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors , 2014, Oncotarget.

[85]  C. Breitbach,et al.  Going viral with cancer immunotherapy , 2014, Nature Reviews Cancer.

[86]  T. Hickish,et al.  Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. , 2014, The Lancet. Oncology.

[87]  Deepak Mittal,et al.  New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. , 2014, Current opinion in immunology.

[88]  R. Weichselbaum,et al.  Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. , 2014, The Journal of clinical investigation.

[89]  P. Coulie,et al.  Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy , 2014, Nature Reviews Cancer.

[90]  S. Rosenberg,et al.  Exploiting the curative potential of adoptive T‐cell therapy for cancer , 2014, Immunological reviews.

[91]  R. Johnstone,et al.  An intact immune system is required for the anticancer activities of histone deacetylase inhibitors. , 2013, Cancer research.

[92]  C. Mai,et al.  Should a Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancers , 2013, OncoTargets and therapy.

[93]  L. Rimsza,et al.  Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B‐cell lymphoma , 2013, Immunology.

[94]  S. Lowe,et al.  p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells , 2013, The Journal of experimental medicine.

[95]  C. Wells,et al.  LKB1 tumor suppressor regulates AMP kinase/mTOR-independent cell growth and proliferation via the phosphorylation of Yap , 2013, Oncogene.

[96]  A. Alavi,et al.  A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma , 2013, Clinical Cancer Research.

[97]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[98]  Feng Cong,et al.  Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma , 2013, Proceedings of the National Academy of Sciences.

[99]  R. Vonderheide,et al.  Inflammatory networks and immune surveillance of pancreatic carcinoma. , 2013, Current opinion in immunology.

[100]  B. Tycko,et al.  Hypomethylating therapy in an aggressive stroma-rich model of pancreatic carcinoma. , 2013, Cancer research.

[101]  T. Hagemann,et al.  The tumor microenvironment at a glance , 2012, Journal of Cell Science.

[102]  Derek S. Chan,et al.  The Pancreas Cancer Microenvironment , 2012, Clinical Cancer Research.

[103]  O. Joffre,et al.  Cross-presentation by dendritic cells , 2012, Nature Reviews Immunology.

[104]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[105]  N. Jhala,et al.  Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. , 2012, Cancer cell.

[106]  D. Bar-Sagi,et al.  Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. , 2012, Cancer cell.

[107]  N. Lemoine,et al.  Systemic Delivery of Oncolytic Viruses: Hopes and Hurdles , 2012, Advances in virology.

[108]  T. Jacks,et al.  Expression of tumour-specific antigens underlies cancer immunoediting , 2011, Nature.

[109]  J. Herman,et al.  Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. , 2011, Cancer discovery.

[110]  K. Murphy,et al.  Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells , 2011, The Journal of experimental medicine.

[111]  Gerald C. Chu,et al.  PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network. , 2011, Cancer discovery.

[112]  A. Hemminki,et al.  Switching the fiber knob of oncolytic adenoviruses to avoid neutralizing antibodies in human cancer patients , 2011, The journal of gene medicine.

[113]  Marc Liesa,et al.  Pancreatic cancers require autophagy for tumor growth. , 2011, Genes & development.

[114]  T. Keck,et al.  Neutrophil granulocyte derived MMP-9 is a VEGF independent functional component of the angiogenic switch in pancreatic ductal adenocarcinoma , 2011, Angiogenesis.

[115]  R. Schreiber,et al.  Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.

[116]  K. Lillemoe,et al.  A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma: A Phase II Trial of Safety, Efficacy, and Immune Activation , 2011, Annals of surgery.

[117]  I. Yang,et al.  Implications for immunotherapy of tumor-mediated T-cell apoptosis associated with loss of the tumor suppressor PTEN in glioblastoma , 2010, Journal of Clinical Neuroscience.

[118]  S. Rosenberg,et al.  Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma , 2010, Journal of immunotherapy.

[119]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[120]  Z. Guo,et al.  The Combination of Immunosuppression and Carrier Cells Significantly Enhances the Efficacy of Oncolytic Poxvirus in the Pre-Immunized Host , 2010, Gene Therapy.

[121]  B. Kaur,et al.  Impact of tumor microenvironment on oncolytic viral therapy. , 2010, Cytokine & growth factor reviews.

[122]  R. Alemany,et al.  Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study , 2010, Cancer Gene Therapy.

[123]  R. Shaw,et al.  The LKB1–AMPK pathway: metabolism and growth control in tumour suppression , 2009, Nature Reviews Cancer.

[124]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[125]  J. Parsons,et al.  Focal Adhesion Kinase: Targeting Adhesion Signaling Pathways for Therapeutic Intervention , 2008, Clinical Cancer Research.

[126]  Q. Yao,et al.  Elevated interleukin-6 and G-CSF in human pancreatic cancer cell conditioned medium suppress dendritic cell differentiation and activation. , 2007, Cancer research.

[127]  M. Azuma,et al.  Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer , 2007, Clinical Cancer Research.

[128]  R. Vonderheide.  Prospect of Targeting the CD40 Pathway for Cancer Therapy , 2007, Clinical Cancer Research.

[129]  Carlos Cordon-Cardo,et al.  Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas , 2007, Nature.

[130]  P. Pandolfi,et al.  Essential Role for Nuclear PTEN in Maintaining Chromosomal Integrity , 2007, Cell.

[131]  G. Gaudernack,et al.  Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study , 2006, British Journal of Cancer.

[132]  H. Clevers,et al.  Wnt signalling in stem cells and cancer , 2005, Nature.

[133]  G. Prendergast,et al.  Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy , 2005, Nature Medicine.

[134]  R. Schreiber,et al.  The three Es of cancer immunoediting. , 2004, Annual review of immunology.

[135]  T. Gajewski,et al.  Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[136]  Lawrence M Wein,et al.  Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. , 2003, Cancer research.

[137]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[138]  G. Freeman,et al.  Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.

[139]  J. Herman,et al.  Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. , 2000, Cancer research.

[140]  H. Friess,et al.  Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[141]  J. Allison,et al.  Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.

[142]  G. Stark,et al.  The protein tyrosine kinase JAK1 complements defects in interferon-α/β and -γ signal transduction , 1993, Nature.

[143]  Jinping Li,et al.  Dkk1 involvement and its potential as a biomarker in pancreatic ductal adenocarcinoma. , 2019, Clinica chimica acta; international journal of clinical chemistry.

[144]  P. Singh,et al.  Evaluation of Macrophage Polarization in Pancreatic Cancer Microenvironment Under Hypoxia. , 2018, Methods in molecular biology.

[145]  Jason B. Williams,et al.  Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment. , 2017, Advances in experimental medicine and biology.

[146]  J. Kench,et al.  Hypermutation In Pancreatic Cancer. , 2017, Gastroenterology.

[147]  Shelly A Bambina,et al.  Radiotherapy Combined with Novel STING-Targeting Oligonucleotides Results in Regression of Established Tumors. , 2016, Cancer research.

[148]  P. Ye,et al.  Histone deacetylase 11 regulates oligodendrocyte‐specific gene expression and cell development in OL‐1 oligodendroglia cells , 2009, Glia.

[149]  P. Atadja,et al.  The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance , 2009, Nature Immunology.

[150]  Gavin P Dunn,et al.  Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. , 2006, Advances in immunology.

[151]  S. Minucci,et al.  Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer , 2006, Nature Reviews Cancer.

[152]  C. Benz,et al.  Clinical development of histone deacetylase inhibitors as anticancer agents. , 2005, Annual review of pharmacology and toxicology.

[153]  R. Flavell,et al.  CD40 and CD154 in cell-mediated immunity. , 1998, Annual review of immunology.

[154]  M Aguet,et al.  The IFN gamma receptor: a paradigm for cytokine receptor signaling. , 1997, Annual review of immunology.